Top stories published by #InsightNetwork | ATAI Life Sciences AG in 2020

Homepage

Open in app

Top Stories published by #InsightNetwork | ATAI Life Sciences AG in 2020

All

2020

January

February

March

April

May

June

July

August

September

October

November

December

ATAI MEDIA in #InsightNetwork | ATAI Life Sciences AG

Feb 13, 2020

Impact of the Depression Epidemic: Family & Community

ATAI MEDIA in #InsightNetwork | ATAI Life Sciences AG

Feb 16, 2020

EntheogeniX Biosciences gets going

Psilocybin, ibogaine, and many other psychedelic substances have yielded remarkable early signals…

ATAI MEDIA in #InsightNetwork | ATAI Life Sciences AG

Mar 22, 2020

Mental health in a time of COVID-19

Whether you’re on lockdown or just practicing social distancing, chances are you’re beginning to…

ATAI MEDIA in #InsightNetwork | ATAI Life Sciences AG

Feb 13, 2020

Terence Kelly appointed CEO of ATAI platform company Perception Neuroscience

ATAI MEDIA in #InsightNetwork | ATAI Life Sciences AG

Feb 13, 2020

ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder

ATAI MEDIA in #InsightNetwork | ATAI Life Sciences AG

Feb 13, 2020

GABA Therapeutics commences phase I study of Etifoxine

ATAI MEDIA in #InsightNetwork | ATAI Life Sciences AG

Feb 13, 2020

ATAI’s Chief Scientific Officer addresses the future of psychiatric drug development at ISAD19

ATAI MEDIA in #InsightNetwork | ATAI Life Sciences AG

Feb 13, 2020

These were the top 10 stories published by #InsightNetwork | ATAI Life Sciences AG in 2020. You can also dive into monthly archives for 2020 by using the calendar at the top of this page.

About

#InsightNetwork | ATAI Life Sciences AG

The latest in the field of biotech, psychedelic medicine, and mental health research. Working to transform the paradigm of mental health by raising awareness, providing information, and sharing insights. Lets bridge the gaps together. Learn more at ATAI.life.

More information

Impact of the Depression Epidemic: Family & Community

EntheogeniX Biosciences gets going

Mental health in a time of COVID-19

Terence Kelly appointed CEO of ATAI platform company Perception Neuroscience

ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder

GABA Therapeutics commences phase I study of Etifoxine

ATAI’s Chief Scientific Officer addresses the future of psychiatric drug development at ISAD19

Inequality: An overlooked contributor to mental health disorders (part 1)

Reflections on the progress of psychedelic medicine

Gender Disparities and Mental Health Risk Factors